Narrow your search
Listing 1 - 9 of 9
Sort by

Book
Résistance aux traitements de l'hépatite C, quelle utilité clinique ?
Authors: --- ---
Year: 2018 Publisher: Bruxelles: UCL. Faculté de pharmacie et des sciences biomédicales,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Hepatitis C disease approximately affects 200 000 people every day. It’s a monocatenary virus which is wrapped, small-sized and belongs to the Flaviviridae family. It presents a high genetic variability. There are actually 6 genotypes going from 1 to 6 and sub-genotypes (a and b). Time is incubation is very variable; it can achieve 26 weeks. We can see a big fatigue, an icterus and abdominal pains. Disease can evolve into a fibrosis even a cirrhosis. The first available treatment, since 1990 is the interferon associated with ribavirine. This treatment is very badly tolerated by the patients. It presents too many side effects among fatigue, headaches, myalgias even haematological disorders. Then appeared inhibitors of the protease NS3/4A, boceprevir, telaprevir and simeprevir; NS5A’S inhibitors, ledipasvir and dactalasvir ; and sofosbuvir, which is the ARN polymerase NS5B’s inhibitor. Treatment’s choice depends on the genotype. Some treatments can end in failures because of patient’s lack of compliance or resistances. Sofosbuvir possesses the highest barrier of resistance, contrary to protease’s inhibitors. To avoid failures, combination therapies are recommended with sofosbuvir or ribavirine. For each class of medicine, it’s necessary to know the transfers having a clinical impact to optimize the treatment. However searching for mutations is not systematic. It also depends on the genotype. Furthermore, mutations can persist after stopping treatment and others can return to wild origin, like telaprevir. Research for mutations causing resistance must be individually studied. L’hépatite C touche environ 200 000 personnes chaque année. C’est un virus à ARN monocaténaire, enveloppé, de petite taille qui appartient à la famille des Flaviviridae. Il présente une grande variabilité génétique. Il existe 6 génotypes allant de 1 à 6 et des sous-génotypes ( a et b). Le temps d’incubation est très variable peut atteindre 26 semaines. Cela se manifeste par une grande fatigue, un ictère et des douleurs abdominales. La maladie peut évoluer vers une fibrose voire une cirrhose. Le premier traitement disponible, depuis 1990 est l’interféron associé à la ribavirine. Ce traitement est très mal toléré par les patients. Il présente trop d’effets secondaires dont la fatigue, des maux de tête, des myalgies voire des troubles hématologiques. Ensuite, sont apparus les inhibiteurs de la protéase NS3/4A : le boceprevir, le telaprevir et le simeprevir ; les inhibiteurs de la NS5A : le ledispavir et le daclatasvir ; et le sofosbuvir : inhibiteur de l’ARN polymerase NS5B. Le choix du traitement dépend du génotype. Ces traitements peuvent parfois aboutir à des échecs à cause du manque de compliance du patient ou de résistances. Le sofosbuvir possède la barrière de résistance la plus élevée, contrairement aux inhibiteurs de la protéase. Pour contrecarrer les échecs, des associations médicamenteuses sont recommandées avec le sofosbuvir ou la ribavirine. Pour chaque classe de médicament, il est nécessaire de connaître les mutations ayant un impact systématique. Cela dépend du génotype. De plus, certaines mutations persistent après l’arrêt du traitement et d’autres retournent à la souche sauvage, c’est le cas du telaprevir. L’utilité de la recherche de mutations provoquent des résistances est à étudier au cas par cas.


Book
Mise en évidence de mutations conférant une résistance au virus de l'immunodéficience humaine de type 2 (HIV-2) vis-à-vis des inhibiteurs nucléosidiques de la transciptase inverse
Authors: --- ---
Year: 2004 Publisher: Bruxelles: UCL,

Loading...
Export citation

Choose an application

Bookmark

Abstract

HIV type 2 is the second immunodeficiency virus to infect humans and like HIV-1, the virus is known to cause AIDS. The activity of current antiretroviral drugs is not well established in HIV-2- infected patients and data available on the development of drug resistance in vivo are scare.
The first aim of this work concerns the set up of a method inducing the emergence of resistance mutations. Two strains ROD and EHO, belonging respectively to subtype A and B, are used to infect H9 cell culture in the presence of nucleoside reverse transcriptase inhibitor. Three molecules are tested: ziduvudine (AZT), lamivudine (3TC) and abacavir (ABC). In parallel, a PCR amplification was developed to sequence the RT gene of cultured strains and clinical samples.
The drug concentration used in culture was chosen with regard to the IC50 determined by a viability assay; the MTT test on MT-4 cells. This assay also enables us to determine the sensitivity of a mutant strain to a drug. We have obtained EHO and ROD virus bearing the M184V mutation known to induce resistance to lamivudine in HIV-1.
No mutation was detected with AZT , even by multiplying more than 5000 times its concentration. On the basis of kinetic assays, no AZT activity was observed in H9 cells.
The sequencing of several HIV-2 infected patients confirmed that PCR with the primers specific for ROD, belonging to the most frequently subtype, is applicable to clinical samples to a certain extent. The genotype of two patients treated with Trizivir®(AZT-3TC-ABC) showed primary M184V and Q151M mutations, known in HIV-1 and already described among HIV-2 infected patients, and also some others mutations previously undescribed HIV type 2 est le second virus de l’immunodéficience à infecter des humains à l’instar du virus HIV-1, il est associé au syndrome d’immunodéficience acquise (SIDA). L’activité et l’efficacité des antirétroviraux ne sont pas encore clairement établies chez des patients infectés par le deuxième type de virus HIV. De même, des données concernant l’émergence, in vivo, de mutations de résistances restent rares.
Le premier objectif de ce travail consiste à développer une méthode induisant l’apparition de mutations conférant une résistance au virus HIV2. Deux souches virales, ROD et EHO respectivement de sous-type A et B, sont utilisées pour infecter des cellules H9 en ªªªªsont testés : la zidovudine (AZT), la lamivudine (3tc) et l’abacavir (ABC). En parallèle, une réaction de PCR erst mise au point afin de permettre la séquençage de gène de la transcriptase inverse des souches virales issues des cultures cellulaires et celles isolées à partir d’échantillons cliniques.
La concentration de médicaments utilisée en culture correspond à l’IC50, déterminée par un test de viabilité cellulaire ; le test MTT réalisé sur des cellules MT -4. Cette technique permet également de déterminer la sensibilité d’une souche mutée vis-à-vis d’un antirétroviral.
Deux souches virales ROD et EHO arborant la mutation M184V ont été obtenues. Cette mutation est connue pour conférer au virus HIV-1 une résistance à la lamivudine. Aucune mutation spécifique de la zidovudine n’a pu être détectée, même en multipliant plus de 5000 fois sa concentration. Sur base d’un test cinétique, aucune activité de l’AZT n’a pu être observée chez des cellules H9 infectées.
Le séquençage de plusieurs patients infectés par HIV-2 a confirmé que l’utilisation d’amorces spécifiques à ROD, appartenant au sous-type le plus fréquemment rencontré, est applicable dans une certaine mesure à des échantillons cliniques. Le génotypage d’un patient traité avec du Trizivir® (AZT-3TC-ABC) a pu mettre en évidence les mutations primaires M184V et Q151M, connues pour HIV-1 et déjà décrites chez des patients HIV-2 positifs, ainsi que d’autres mutations inconnues jusqu’à présent


Periodical
Virus adaptation and treatment.
Year: 2009 Publisher: [Auckland, N.Z.] : Dove Medical Press,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Periodical
Virus Adaptation and Treatment
ISSN: 11791624 Publisher: Place of publication unknown publisher unknown

Loading...
Export citation

Choose an application

Bookmark

Abstract


Periodical
Virus adaptation and treatment.
Year: 2009 Publisher: [Auckland, N.Z.] : Dove Medical Press,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Periodical
Virus adaptation and treatment.
Year: 2009 Publisher: [Auckland, N.Z.] : Dove Medical Press,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
Antiretroviral resistance in clinical practice
Authors: ---
ISBN: 095516690X Year: 2006 Publisher: [Place of publication not identified] Mediscript

Frontiers in viral hepatitis
Authors: --- ---
ISBN: 9780444509864 0444509860 Year: 2003 Publisher: [Place of publication not identified] Elsevier

Loading...
Export citation

Choose an application

Bookmark

Abstract

Frontiers in Viral Hepatitis provides a compilation of the research from over 40 key opinion leaders in the field of Hepatitis. The book focuses on the latest advances in the search for new, more effective therapeutic options and related topics in viral hepatitis. These include regulatory issues, epidemiology, and emerging viruses; immunology and vaccines; viral hepatitis B and C infections in children; genetics pathology and viral diagnosis; cell systems and animal models; novel therapeutics for hepatitis B and C; resistance and therapeutic strategies in humans; and prevention and treatment options for hepatocellular carcinoma. The breadth of information published in this volume provides insight into current prevention and treatment options. Recent advances in our understanding of the molecular biology, immunology and pathogenesis of hepatitis viruses have accelerated at a remarkable rate, offering a more comprehensive perspective on hepatitis.

Frontiers in viral hepatitis
Authors: --- ---
ISBN: 9780444509864 0444509860 Year: 2003 Publisher: Amsterdam Boston Elsevier

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords

Human medicine --- Hepatitis, Viral, Human --- Liver Neoplasms --- Flaviviridae Infections --- Drug Resistance, Microbial --- Virus Physiological Phenomena --- Hepadnaviridae Infections --- Adenocarcinoma --- Carcinoma, Hepatocellular --- Hepatitis C --- Drug Resistance, Viral --- Hepatitis B --- Hepatitis --- Microbiological Phenomena --- Digestive System Neoplasms --- Drug Resistance --- Virus Diseases --- Carcinoma --- DNA Virus Infections --- RNA Virus Infections --- Liver Diseases --- Digestive System Diseases --- Neoplasms by Site --- Diseases --- Phenomena and Processes --- Neoplasms, Glandular and Epithelial --- Pharmacological Phenomena --- Neoplasms --- Neoplasms by Histologic Type --- Physiological Phenomena --- Medicine --- Gastroenterology --- Health & Biological Sciences --- Physiological Concepts --- Physiological Phenomenon --- Physiological Process --- Physiological Processes --- Concept, Physiological --- Concepts, Physiological --- Phenomena, Physiological --- Phenomenas, Physiological --- Phenomenon, Physiological --- Physiological Concept --- Process, Physiological --- Processes, Physiological --- Histological Type of Neoplasm --- Histological Types of Neoplasms --- Neoplasms by Histological Type --- Neoplasm Histological Type --- Neoplasm Histological Types --- Neoplasms Histological Type --- Neoplasms Histological Types --- Benign Neoplasms --- Malignancy --- Malignant Neoplasms --- Neoplasia --- Neoplasm --- Neoplasms, Benign --- Cancer --- Tumors --- Benign Neoplasm --- Cancers --- Malignancies --- Malignant Neoplasm --- Neoplasias --- Neoplasm, Benign --- Neoplasm, Malignant --- Neoplasms, Malignant --- Tumor --- Medical Oncology --- Pharmacologic Phenomena --- Pharmacologic Phenomenon --- Pharmacologic Process --- Pharmacological Concepts --- Pharmacological Phenomenon --- Pharmacologic Processes --- Pharmacological Processes --- Concept, Pharmacological --- Concepts, Pharmacological --- Pharmacological Concept --- Phenomena, Pharmacologic --- Phenomena, Pharmacological --- Phenomenon, Pharmacologic --- Phenomenon, Pharmacological --- Process, Pharmacologic --- Processes, Pharmacologic --- Processes, Pharmacological --- Epithelial Neoplasms --- Glandular Neoplasms --- Glandular and Epithelial Neoplasms --- Neoplasms, Epithelial --- Neoplasms, Glandular --- Neoplasms, Glandular Epithelial --- Epithelial Neoplasm --- Epithelial Neoplasm, Glandular --- Epithelial Neoplasms, Glandular --- Glandular Epithelial Neoplasm --- Glandular Epithelial Neoplasms --- Glandular Neoplasm --- Neoplasm, Epithelial --- Neoplasm, Glandular --- Neoplasm, Glandular Epithelial --- Neoplasms by Sites --- Site, Neoplasm --- Sites, Neoplasm --- Neoplasm Site --- Neoplasm Sites --- Digestive System Disorders --- Hepatobiliary Diseases --- Hepatobiliary Disorders --- Digestive System Disease --- Digestive System Disorder --- Hepatobiliary Disease --- Hepatobiliary Disorder --- System Disorders, Digestive --- Liver Dysfunction --- Disease, Liver --- Diseases, Liver --- Dysfunction, Liver --- Dysfunctions, Liver --- Liver Disease --- Liver Dysfunctions --- Infections, RNA Virus --- Infection, RNA Virus --- RNA Virus Infection --- Virus Infection, RNA --- Virus Infections, RNA --- Infections, DNA Virus --- DNA Virus Infection --- Infection, DNA Virus --- Virus Infection, DNA --- Virus Infections, DNA --- Epithelial Tumors, Malignant --- Malignant Epithelial Neoplasms --- Neoplasms, Malignant Epithelial --- Carcinoma, Anaplastic --- Carcinoma, Spindle-Cell --- Carcinoma, Undifferentiated --- Carcinomatosis --- Epithelial Neoplasms, Malignant --- Epithelioma --- Anaplastic Carcinoma --- Anaplastic Carcinomas --- Carcinoma, Spindle Cell --- Carcinomas --- Carcinomatoses --- Epithelial Neoplasm, Malignant --- Epithelial Tumor, Malignant --- Epitheliomas --- Malignant Epithelial Neoplasm --- Malignant Epithelial Tumor --- Malignant Epithelial Tumors --- Neoplasm, Malignant Epithelial --- Spindle-Cell Carcinoma --- Spindle-Cell Carcinomas --- Tumor, Malignant Epithelial --- Undifferentiated Carcinoma --- Undifferentiated Carcinomas --- Viral Diseases --- Viral Infections --- Virus Infections --- Disease, Viral --- Disease, Virus --- Diseases, Viral --- Diseases, Virus --- Infection, Viral --- Infection, Virus --- Infections, Viral --- Infections, Virus --- Viral Disease --- Viral Infection --- Virus Disease --- Virus Infection --- Resistance, Drug --- Pharmacogenetics --- Cancer of the Digestive System --- Neoplasms, Digestive System --- Cancer of Digestive System --- Digestive System Cancer --- Cancer, Digestive System --- Cancers, Digestive System --- Digestive System Cancers --- Digestive System Neoplasm --- Neoplasm, Digestive System --- Microbial Concepts --- Microbial Phenomena --- Microbiologic Concepts --- Microbiological Phenomenon --- Microbiological Process --- Phenomena, Microbiologic --- Microbiologic Phenomena --- Microbiological Processes --- Concept, Microbial --- Concept, Microbiologic --- Concepts, Microbial --- Concepts, Microbiologic --- Microbial Concept --- Microbiologic Concept --- Phenomena, Microbial --- Phenomena, Microbiological --- Phenomenon, Microbiological --- Process, Microbiological --- Processes, Microbiological --- Dysbiosis --- Hepatitides --- Hepatitis B Virus Infection --- Antiviral Drug Resistance --- Antiviral Drug Resistances --- Drug Resistances, Viral --- PT-NANBH --- Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted --- Parenterally-Transmitted Non-A, Non-B Hepatitis --- Parenterally Transmitted Non A, Non B Hepatitis --- Liver Cancer, Adult --- Liver Cell Carcinoma --- Liver Cell Carcinoma, Adult --- Hepatocellular Carcinoma --- Hepatoma --- Adult Liver Cancer --- Adult Liver Cancers --- Cancer, Adult Liver --- Cancers, Adult Liver --- Carcinoma, Liver Cell --- Carcinomas, Hepatocellular --- Carcinomas, Liver Cell --- Cell Carcinoma, Liver --- Cell Carcinomas, Liver --- Hepatocellular Carcinomas --- Hepatomas --- Liver Cancers, Adult --- Liver Cell Carcinomas --- Adenocarcinoma, Basal Cell --- Adenocarcinoma, Granular Cell --- Adenocarcinoma, Oxyphilic --- Adenocarcinoma, Tubular --- Adenoma, Malignant --- Carcinoma, Cribriform --- Carcinoma, Granular Cell --- Carcinoma, Tubular --- Adenocarcinomas --- Adenocarcinomas, Basal Cell --- Adenocarcinomas, Granular Cell --- Adenocarcinomas, Oxyphilic --- Adenocarcinomas, Tubular --- Adenomas, Malignant --- Basal Cell Adenocarcinoma --- Basal Cell Adenocarcinomas --- Carcinomas, Cribriform --- Carcinomas, Granular Cell --- Carcinomas, Tubular --- Cribriform Carcinoma --- Cribriform Carcinomas --- Granular Cell Adenocarcinoma --- Granular Cell Adenocarcinomas --- Granular Cell Carcinoma --- Granular Cell Carcinomas --- Malignant Adenoma --- Malignant Adenomas --- Oxyphilic Adenocarcinoma --- Oxyphilic Adenocarcinomas --- Tubular Adenocarcinoma --- Tubular Adenocarcinomas --- Tubular Carcinoma --- Tubular Carcinomas --- Carcinoma, Non-Small-Cell Lung --- Infections, Hepadnaviridae --- Hepadnaviridae Infection --- Infection, Hepadnaviridae --- Physiology, Viral --- Viral Physiological Concepts --- Viral Physiological Phenomena --- Viral Physiological Process --- Virus Physiological Concepts --- Virus Physiological Phenomenon --- Virus Physiological Process --- Virus Physiology --- Viral Physiological Processes --- Viral Physiology --- Virus Physiological Processes --- Concept, Viral Physiological --- Concept, Virus Physiological --- Concepts, Viral Physiological --- Concepts, Virus Physiological --- Phenomena, Viral Physiological --- Phenomena, Virus Physiological --- Phenomenon, Virus Physiological --- Phenomenons, Virus Physiological --- Physiological Process, Viral --- Physiological Process, Virus --- Physiological Processes, Viral --- Physiological Processes, Virus --- Physiology, Virus --- Process, Viral Physiological --- Process, Virus Physiological --- Processes, Viral Physiological --- Processes, Virus Physiological --- Viral Physiological Concept --- Virus Physiological Concept --- Viruses --- Antimicrobial Drug Resistance --- Antibiotic Resistance --- Antibiotic Resistance, Microbial --- Antimicrobial Drug Resistances --- Drug Resistances, Microbial --- Resistance, Antibiotic --- Microbial Sensitivity Tests --- Infections, Flaviviridae --- Flaviviridae Infection --- Infection, Flaviviridae --- Cancer of the Liver --- Cancer, Hepatocellular --- Hepatic Neoplasms --- Hepatocellular Cancer --- Neoplasms, Hepatic --- Neoplasms, Liver --- Cancer of Liver --- Hepatic Cancer --- Liver Cancer --- Cancer, Hepatic --- Cancer, Liver --- Cancers, Hepatic --- Cancers, Hepatocellular --- Cancers, Liver --- Hepatic Cancers --- Hepatic Neoplasm --- Hepatocellular Cancers --- Liver Cancers --- Liver Neoplasm --- Neoplasm, Hepatic --- Neoplasm, Liver --- Viral Hepatitis, Human --- Human Viral Hepatitides --- Human Viral Hepatitis --- Viral Hepatitides, Human --- physiology --- Epithelial Cell Neoplasms --- Glandular Cell Neoplasms --- Cell Neoplasm, Epithelial --- Cell Neoplasm, Glandular --- Cell Neoplasms, Epithelial --- Epithelial Cell Neoplasm --- Glandular Cell Neoplasm --- Neoplasm, Epithelial Cell --- Neoplasm, Glandular Cell

Listing 1 - 9 of 9
Sort by